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Cardiac implantable electronic device–related infection is clin-
ically challenging. Curative treatment commonly includes sys-
tem removal. A case caused by Granulicatella adiacens occurred 
in a 32-year-old woman. Clinical course, literature review, and 
biofilm investigations enabled successful antibiotic manage-
ment without system removal.
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Cardioverter defibrillator and cardiac resynchronization ther-
apy devices are increasingly implanted. Infection related to 
these devices (ie, cardiac implantable electronic device [CIED]–
related infection) is associated with significant morbidity and 
mortality and considerable healthcare costs [1]. Expert con-
sensus statements and national guidelines have proposed treat-
ment algorithms for CIED-related infections [2–5]. Curative 
treatment requires complete device system removal and antimi-
crobial therapy. Although lead extraction is a safe intervention 
in the majority of cases, complications are associated with high 
mortality rates.
There are considerable differences in biofilm production 
between various bacterial species and within each species of 
microorganism. These differences have the potential to be use-
ful for decision making during the treatment of biofilm-related 
infection. We present a case of CIED-related infection and 
bioprosthesis endocarditis caused by Granulicatella adiacens. 
Results of antimicrobial susceptibility testing and biofilm inves-
tigations together with results from a literature review aided 
interdisciplinary decision making for the successful manage-
ment of the infection without device system removal.
CASE REPORT
A 32-year-old woman was referred to our center with a diag-
nosis of CIED-related infection and bioprosthesis endocarditis. 
She was born with complex congenital heart disease (CHD) 
that included a complete transposition of the great arteries, a 
small ventricular septal defect and severe pulmonary valve 
stenosis. A Rashkind procedure was conducted in the neona-
tal period. When she was 6 years old, a Rastelli procedure was 
performed: left ventricular output was rerouted by a ventricular 
septal defect closure patch to the transposed aorta, and right 
ventricular output was rerouted by a surgically placed conduit 
to the pulmonary artery (RV-PA conduit; see Supplementary 
Figure 1). An epicardial pacemaker was implanted during the 
immediate postoperative course because of a complete atrio-
ventricular block. 
When the patient was 11 years old, her severely stenotic pul-
monary conduit (a pulmonary homograft) was replaced with 
a new conduit containing a 25-mm biological valve prosthesis 
(Carpentier-Edwards). When she was 14  years old, an endo-
venous automatic implantable cardioverter defibrillator was 
implanted, after she was resuscitated because of ventricular 
tachycardia. A new right ventricular defibrillator electrode was 
implanted when she was 29 years old because of lead failure of 
the shock electrode.
In December 2015, the patient presented with a 2-day his-
tory of fever (38.8°C), chills, shortness of breath, and thoracic 
pain. A chest-radiograph showed no remarkable findings (see 
Supplementary Figure 2A). A  computed tomographic (CT) 
scan demonstrated pulmonary embolism with subsequent 
infarction in the lower left lobe. These findings were subse-
quently confirmed by fludeoxyglucose F 18 positron emission 
tomography/CT (FDG PET/CT) (see Supplementary Figure 
2B). G.  adiacens grew in 3 sets of blood cultures (each con-
sisting of an aerobic and an anaerobic bottle) obtained over 36 
hours (0, 28, and 36 hours after admission). The first 2 pairs 
of blood cultures were obtained without antibiotic treatment. 
Empiric intravenous (treatment with amoxicillin-clavula-
nate was started 4 hours before the third set of cultures was 
obtained. Transthoracic and transoesophageal echocardiog-
raphy was performed, along with FDG PET/CT, and none of 
these modalities revealed findings consistent with native valve, 
RV-PA conduit, or CIED infection. 
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Based on the presence of 1 major and 3 minor Duke crite-
ria (major: continuous bacteremia with G.  adiacens over 36 
hours; minor: fever, predisposition, and septic pulmonary 
infarction), the diagnosis of CIED-related infection and con-
duit endocarditis was made. Targeted intravenous antimicro-
bial treatment consisted of penicillin G (4 million units every 
4 hours) and gentamicin (3 mg/kg body weight [170 mg] once 
daily). Follow-up blood cultures remained negative. Removal 
of the implanted cardiac device system and replacement of the 
conduit were discussed. In light of her medical history and the 
surgical risks (third sternotomy), the patient was reluctant to 
undergo surgery for removal and replacement of the device.
Antimicrobial susceptibility investigations revealed that the 
causative pathogen displayed low minimal inhibitory concen-
trations (MICs). Biofilm assays indicated poor biofilm produc-
tion. An interdisciplinary team decided to continue therapy 
with a conservative but curative treatment approach, together 
with therapeutic drug monitoring. After 2 weeks of penicil-
lin-gentamicin combination therapy, treatment was switched to 
ceftriaxone (2 g once daily, given intravenously) for 4 weeks, fol-
lowed by amoxicillin (1 g taken orally, 3 times daily) for another 
6 weeks (ie, for a total treatment duration of 12 weeks). Several 
clinical, laboratory, and echocardiographic follow-up investiga-
tions over a 3-year period showed no relapse of infection.
METHODS AND RESULTS
Susceptibility Tests
MICs were determined using Etests (bioMérieux) on Mueller-
Hinton sheep blood agar plates. Streptococcus pneumoniae 
American Type Culture Collection 49619 strain was used for 
quality control. The MIC results were as follows for penicillin, 
amoxicillin, ceftriaxone, rifampin, respectively: 0.006, 0.016, 
0.016, and, 0.002 µg/mL.
Serum Concentrations of Administered Antimicrobial Agents
Antibiotic concentrations were measured via high-performance 
liquid chromatography-mass spectrometry. The penicillin 
serum concentration (trough level, 4 hours after last adminis-
tration [infusion no. 21]) was 3.25 µg/mL at day 4 of treatment. 
The trough serum level of amoxicillin (oral intake no. 13) was 
1.5 µg/mL at day 5 of amoxicillin therapy. The trough serum 
values for penicillin G and amoxicillin were more than 540 and 
93 times, respectively, above the MICs. Considering protein 
binding proportions of 45%–65% for penicillin G and 15%–
20% for amoxicillin, the results indicated  that the free drug 
concentrations remained above the MIC (fT > MIC of 100%) 
for planktonic bacteria in serum.
Biofilm Formation Assays
The extent of biofilm formation was quantified via absorp-
tion of crystal violet dye at 550 nm, after 24, 48 and 72 hours 
of incubation. (See Supplementary Material for details on 
methods.) Four bacterial strains were used for comparison: 2 
Staphylococcus aureus strains (a clinical isolate obtained from a 
patient with a proved CIED-related infection [SAU6110.50] and 
a laboratory quality control strain [SAU22]) and 2 Pseudomonas 
aeruginosa strains (a clinical isolate from a patient with cystic 
fibrosis [PA401] and a laboratory quality control strain [PA20]).
Aggregation of bacteria was macroscopically evident in broth 
incubating P. aeruginosa (Figure 1A). The results of poor crys-
tal violet staining of G. adiacens were seen, along with marked 
differences between S. aureus or P. aeruginosa and G. adiacens 
(Figure 1B and 1C).
We then performed biofilm formation assays on bone cement 
beads and coverslips (see Supplementary Material for details). 
After 48-hour incubation and removal of nonsessile bacteria, 
the number of colony-forming units in biofilm was quantified 
via sonication and visualized with a scanning electron micro-
scope. No bacteria were cultured after sonication (0 colo-
ny-forming units/mL). Consistent with these results, almost no 
adherent bacteria were found in investigations with a scanning 
electron microscope (Figure 1D).
Review of the Literature
The search strategy and details on included cases are listed in 
the Supplementary Material (Supplementary Table 1). We iden-
tified 15 cases with an infection related to an intravascular for-
eign body and due to either Granulicatella or Abiotrophia spp. 
The median patient age was 61.5 years (range, 18–79 years); 3 
patients (20%) were female, and 12 (80%) were male. Infection 
was related to a vascular prosthesis in 2 patients, to a prosthetic 
valve in 11 (73.3%), and to both in 1. One infection was related 
to a pacemaker and a bioprosthesis, a condition similar to our 
case [6]. The aortic valve (8 cases [53.3%]) was most commonly 
involved. In 10 cases (66.6%), the causative microorganism 
was Granulicatella spp., and in 5 (33.3%) it was Abiotrophia 
spp. In 9 cases (60%), no surgical procedure was performed. 
Death occurred in 1 patient. The other 14 cases were classified 
as cured. A follow-up examination was available in 11 patients, 
and in 6 of them the follow-up was ≤6 months.
DISCUSSION
The prevalence of CHD has increased in the past decades. 
This is true for children and even more so for adults [7]. In a 
2018 nationwide study from Denmark, the live-birth incidence 
of CHD was 1.2% and constant over the past 20 years [8]. In 
Switzerland, every year, approximately 700 children are born 
with CHD. Half of them have moderately complex (eg, coarc-
tation of the aorta) or complex (eg, transposition of the great 
arteries) defects. More than 90% of children with repaired CHD 
survive into adulthood [9]. Consequently, the number of adult 
patients with CHD has outgrown the pediatric CHD cohort. 
Two of 3 patients with CHD are adults [7].
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There is an increased risk for infective endocarditis in adults 
with CHD. In the CONCOR adult CHD registry, the incidence 
of endocarditis was 1.33 cases per 1000 person-years. In this 
cohort, valve-containing prosthetics were independently asso-
ciated with a greater risk for endocarditis, even 12  months 
beyond implantation (hazard ratio, 5.26; 95% confidence inter-
val, 3.52–7.86) [10]. In our case, no vegetation was observed in 
repeated echocardiographic images, although typical endocar-
ditis features in RV-PA valved conduits are difficult to detect 
with echocardiography [11]. The sensitivity of the FDG PET/CT 
scan for “lead infection” was reported as 24% (95% CI 5%–54%) 
for the standard method (1 hour) and 61% (95% CI 32%–86%) 
for the delayed method (3 hours) in 1 study [12]. A meta-analy-
sis of this method was proved to have good overall accuracy for 
the diagnosis of CIED-related infections, with a pooled sensi-
tivity of 87% and a specificity of 94% [13]. Although FDG PET/
CT had negative findings in our case, prolonged bacteremia 
and septic pulmonary infarction were convincing arguments 
to postulate CIED-related infection and bioprosthesis endo-
carditis. We were unable to determine whether only part of the 
C
D
A
B
24 h 72 h48 h
Biofilm 24 h
2.0
1.5
1.0
0.5
0.0
A
bs
or
pt
io
n 
at
 5
50
 n
m
TS
B 
+ 
glu
co
se
BH
I +
 L
-cy
ste
ine
BH
I +
 L
-cy
ste
ine
 +
 vi
tam
in 
B6
SAU22
PAE20
NVS
PAE401
SAU6110.50
Figure 1. A, Broth media incubating 2 Staphylococcus aureus strains (clinical isolate obtained from a patient with a proved cardiac implantable electronic device [CIED] 
infection [SAU6110.50] and a laboratory quality control strain [SAU22]) and 2 Pseudomonas aeruginosa strains (clinical isolate from a patient with cystic fibrosis [PA401] 
and a laboratory quality control strain [PAE20]). Aggregation of bacteria was macroscopically evident in broth incubating P. aeruginosa (strain PAE20). B, Crystal violet (CV) 
staining with inocula of 0.5 and 1.0 McFarland (McF) Granulicatella adiacens and incubation durations of 24, 48, and 72 hours. Overall, the dye uptake is poor. C, Differences 
between the CV staining of S. aureus or P. aeruginosa and G. adiacens in the results from absorption measurements (top) and wells (bottom). D, Scanning electron microscopic 
images of the polymethylmethacrylate (PMMA) bead biofilm formation assay show few adherent bacteria (red arrows) detected on the PMMA surface. Abbreviations: BHI, 
brain-heart infusion broth; neg ctrl, negative control; neg, negative control; NVS, nutritionally variant streptococci; TSB, tryptic soy broth.
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device was infected (eg, lead infection) or whether the infection 
involved both bioprosthesis and native valves. In addition, Erba 
et  al [14] reported a low sensitivity for diagnosing device-re-
lated infections using Duke criteria. 
Although conservative treatment for prosthetic valve endo-
carditis may be attempted, removal of the complete system, 
including electrodes, is currently regarded as the standard of 
care for CIED-related infection. The major complication rate 
ranges from 0.7% to 1.9%, depending on the extraction tech-
nique [15]. Major complications may have a high mortality 
risk, particularly in patients with multiple and older leads, 
internal cardioverter and defibrillator leads, or calcified leads 
and in adults with CHD. Complications include hemothorax, 
pericardial effusion, tamponade, pneumothorax, valve damage, 
and thromboembolism. CIED system removal requires a team 
approach by an interventional rhythmologist, a cardiac sur-
geon, a cardiac technician, and an anesthesia team capable of 
providing echocardiographic guidance. Thus, removal is associ-
ated with significant costs, and there are arguments for conser-
vative treatment.
Nutritionally variant streptococci have been regarded as dif-
ficult to eradicate in infective endocarditis. This belief is based 
mainly on treatment failures in 12 of 29 reviewed cases (41%), 
according to a report published in 1987 [16]. In that study, bac-
terial failure was defined as positive blood cultures after 7 days 
of antibiotic therapy, relapse after a course of therapy with 
appropriate antibiotics, or a positive valve culture after therapy. 
A 2018 study on 76 infective endocarditis cases [17], collected 
from 2000 to 2015, showed a low overall mortality rate (13.2% in 
cases due to Abiotrophia spp., 5.2% in those due to Granulicatella 
spp.). This observation is in line with the results from our liter-
ature review. Nutritionally variant streptococci may not always 
be difficult to treat, considering that 9 of 15 cases with an infec-
tion related to a foreign body were successfully treated conser-
vatively. There are considerable differences in MICs, however, 
when comparing susceptibility testing results.
Recommendations for antimicrobial management of CIED 
infection are similar to those for infective endocarditis (ie, ≥4 to 
6 weeks for complicated infection) [2–5]. There are, however, no 
uniform recommendations in the context of device retention. It 
is reasonable that intravenous treatment is followed by oral sup-
pressive therapy. The total treatment duration may be decided 
on an individual case basis, considering multiple variables. In 
our patient, excellent treatment response, the good prognosis 
reflected in the literature review (Supplementary Table 1), and 
the lack of infection signs with repeated echocardiography and 
FDG PET/CT follow-up aided the decision to stop treatment 
after 3 months.
In CIED-related infection, identifying pathogens with poor 
adherence properties may be a step toward a treatment concept 
without device removal. In the past few years, several diag-
nostic concepts in the field of biofilm investigation have been 
developed and critically reviewed [18, 19]. The determination 
of minimal biofilm eradication concentration may reflect a 
phenotypic pattern that is difficult to interpret. In our investi-
gations, biofilm production was assessed with 2 different assays 
that revealed similar results. We assessed biofilm production 
only in a static system of adherence to acrylic glass and bone 
cement and not adherence to wire material. There are no data 
demonstrating the relation of biofilm assay results to clinical 
outcomes in CIED-related infection. However, biofilm investi-
gations of the causative pathogen together with other clinical 
variables may aid interdisciplinary decision making for success-
ful antibiotic management without device system removal.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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